If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-02. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Edward Said asked many times, in public and private, where the Mandela of Palestine could be. In rather bold contrast to this decent imagination, Arafat managed to be both a killer and a compromiser (Mandela was neither), both a Swiss bank account artist and a populist ranter (Mandela was neither), both an Islamic "martyrdom" blow-hard and a servile opportunist, and a man who managed to establish a dictatorship over his own people before they even had a state (here one simply refuses to mention Mandela in the same breath). Hitchens had previously collaborated on this issue with Edward Said, publishing the 1988 book Blaming the Victims: Spurious Scholarship and the Palestinian Question. Hitchens had said of himself, "I am an Anti-Zionist. I'm one of those people of Jewish descent who believes that Zionism would be a mistake even if there were no Palestinians." and "If Jews born in Brooklyn have a right to a state in Palestine, then Palestinians born in Jerusalem have a right to a state in Palestine. Anyone who doesn't agree with that principle I think is suspect." A review of his autobiography Hitch-22 in The Jewish Daily Forward refers to Hitchens "at the time [that he had learned that his grandparents were Jews, he had been] a prominent anti-Zionist" and says that he viewed Zionism "as an injustice against the Palestinians". Others have commented on his anti-Zionism as well.
=== Detection in body fluids === Current clinical laboratory assays for heparin rely on an indirect measurement of the effect of the drug, rather than on a direct measure of its chemical presence. These include activated partial thromboplastin time (APTT) and antifactor Xa activity. The specimen of choice is usually fresh, nonhemolyzed plasma from blood that has been anticoagulated with citrate, fluoride, or oxalate.
== Manufacturing == CPC Scientific’s manufacturing processes primarily use solid-phase peptide synthesis (SPPS), first described by Robert Bruce Merrifield in 1963. SPPS allows peptides to be assembled stepwise on a solid support, enabling the preparation of long and complex sequences for use as active pharmaceutical ingredients (APIs), investigational drugs, and research materials. Researchers associated with the company have published studies involving peptide synthesis methodologies, including work related to hydrocarbon stapling. Products manufactured by the company have been used and cited in various scientific studies.
== Medical uses == Seven controlled efficacy trials were conducted of vilazodone for treatment of major depressive disorder. Five of these trials showed no significant influence of vilazodone over placebo on depressive symptoms. In the remaining two trials, small but significant advantages of vilazodone over placebo were found. According to these two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment. After eight weeks it resulted in a 13% greater response than placebo. Remission rates, however, were not significantly different versus placebo. According to the US Food and Drug Administration (FDA) in 2011, "it is unknown whether vilazodone has any advantages compared to other drugs in the antidepressant class." A 2019 review stated that "present studies do not suggest the superiority of vilazodone compared with other antidepressants." Development of vilazodone for generalized anxiety disorder has been stopped as of 2017. While there is tentative evidence of a small benefit in generalized anxiety disorder, there is a high rate of side effects.
Peukert argued that societies that have reached "classical modernity" are characterized by advanced capitalist economic organization and mass production, by the "rationalization" of culture and society, massive bureaucratization of society, the "spirit of science" assuming a dominant role in popular discourses, and the "social disciplining" and "normalization" of the majority of ordinary people. Peukert was greatly influenced by the theories of Max Weber, but unlike many other scholars, who saw Weber attempting to rebut Karl Marx, he viewed Weber's principal intellectual opponent as Friedrich Nietzsche. Peukert wrote that for Weber, the principal problems of modern Germany were: The increasing "rationalization" of everyday life via bureaucratization and secularism had led to a "complete demystification of the world". The popularity of the "spirit of science" had led to a misguided belief that science could solve all problems within the near-future. Contrary to the "Bielefeld School", Peukert argued by the time of the Weimar Republic, Germany had broken decisively with the past, and had become a thoroughly "modern" society in all its aspects. Peukert argued that the very success of German modernization inspired by the "dream of reason" meant the contradictions and problems of "classical modernity" were felt more acutely in Germany than elsewhere. For Peukert, the problems of "classical modernity" were:
Sources: en.wikipedia.org
With the arrival of Mia and Chloe, producers took the opportunity to explore Ari's fictional backstory further, which Kipa-Williams relished. He thought Ari and Mia were "star-crossed lovers" and believed that Ari had never stopped loving her. The pair soon reconcile, but their relationship is tested by his involvement with a criminal gang and a targeted hit-and-run, which leaves him with serious injuries. Writers scripted a pregnancy for the couple, however, Mia is involved in a car accident during the 2021 mid-season finale, and she has a miscarriage. At the end of the year, Chloe's biological father Matthew Montgomery (James Sweeny) was introduced and Ari takes the blame for his death when Chloe accidentally kills him while protecting Mia. Kipa-Williams quit Home and Away and producers decided to kill-off his character. Ari is admitted to hospital with cancer of the appendix and he opts not to have surgery to remove the tumours, as he wants to die on his terms. Ari and Mia marry shortly before he dies. He made his final appearance on 15 March 2022. Kipa-Williams received a nomination for Best Daytime Star at the Inside Soap Awards in 2020. Ari and the Parata family received a positive response from critics and viewers, with some branding them New Zealand's answer to the River Boys, a popular group of characters introduced in 2011. The character's break-up with Mac was not well received, with Digital Spy's Susannah Alexander and Daniel Kilkelly saying the show had "lost a solid couple".
Moreover, other undetermined proteins may be a part of Ppk1/Ppk26 channel complex, as co-expression of exclusively Ppk and Bba together does not produce mechanosensitive currents. Even very diluted concentrations of velvet ant venom (1:8,192) activate cIV da nociceptors through Ppk1/Ppk26, meaning that the key venom peptide is highly potent and affinitive.
=== Other events === A listening party for the album was held on the rooftop of the Louis Vuitton headquarters in Paris, France on June 23, 2025. Recordings of Lamar's verse on "Chains & Whips" subsequently circulated on social media. At approximately 11 p.m. Eastern Time on July 10, disc jockey and radio personality Ebro Darden hosted a live listening party of the album through Apple Music. An album-signing event was hosted on July 17, 2025, exclusively for customers who purchased a Let God Sort Em Out vinyl via Amoeba Music's Hollywood store.
Half-Life: Escape from City 17 is a two-part Canadian short film written, developed, and filmed by the Purchase Brothers. The film is set in the Half-Life universe, during the events of Half-Life 2 and Half-Life 2: Episode One. Both films were critically acclaimed. Part One was released on February 13, 2009; and Part Two was released on August 24, 2011.
=== Juvenile hormone feedback loop === For the majority of the investigated insect species it has been documented that juvenile hormone stimulates the transcription of the vitellogenin genes and the consequent control of vitellogenin production (cf. Hagedorn and Kunkel, 1979; Engelmann, 1983; Wyatt and Davey, 1996). The vitellogenin expression is part of a regulatory feedback loop that enables vitellogenin and juvenile hormone to mutually suppress each other. Vitellogenin and juvenile hormone likely work antagonistically in the honey bee to regulate the honey bees development and behavior. Suppression of one leads to high titers of the other. It is likely that the balance between vitellogenin and juvenile hormone levels is also involved in swarming behavior. Juvenile hormone levels drop in honey bee colonies pre-swarming and it is expected that vitellogenin levels would therefore rise. One may surmise, that swarming bees would want to pack along as much vitellogenin as possible to extend their lifespan and to be able to quickly build a new nest.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.